SecBot SecBot
Biotech Drug Report Generated Jul 7, 2026

Nexviazyme

SNY·Sanofi
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market since August 2021 (US) for late-onset Pompe disease. Label expansion to infantile-onset Pompe could come in 2027 pending FDA submission and review.
Why 4/10
Nexviazyme is already FDA-approved (2021) and generating ~€790M in annual sales. The next hard catalyst is the H2 2026 FDA submission for infantile-onset Pompe label expansion following positive Phase 3 Baby-COMET results (June 30, 2026). No PDUFA date is set yet. As a part of a €43.6B-revenue diversified pharma giant, even a label-expansion approval would drive a modest single-digit % move in SNY shares at most, not a binary event.
Actionable Insight NEUTRAL

The Baby-COMET Phase 3 topline readout (June 30, 2026) was a positive milestone already priced in. Watch for the formal FDA submission in H2 2026 and the eventual PDUFA decision, likely a 2027 event, which could add ~€100-200M in peak sales from the infantile-onset population. The bigger competitive overhang is BioMarin's newly acquired Pombiliti+Opfolda combo, which Danish regulators found equally effective and which may pressure Sanofi's Pompe franchise pricing.

Price Chart

Loading chart...

Executive Summary

Nexviazyme (avalglucosidase alfa) is Sanofi's next-generation enzyme replacement therapy for Pompe disease, a rare inherited muscle disorder. Approved by the FDA in August 2021 for late-onset Pompe, it generated ~€790M in 2025 sales (Sanofi's total revenue: €43.6B). On June 30, 2026, Sanofi announced positive Phase 3 Baby-COMET results in infantile-onset Pompe, meeting all endpoints, and plans to file for label expansion in H2 2026. The drug faces growing competition from BioMarin's Pombiliti+Opfolda combo (acquired via $4.8B Amicus deal, closed April 2026) and will cannibalize Sanofi's own older ERT Myozyme/Lumizyme. For a diversified pharma giant, Nexviazyme is a steady rare-disease growth asset but not a stock-moving binary event.

How It Works

Nexviazyme is an enzyme replacement therapy (ERT) for Pompe disease, a rare genetic disorder where the body can't break down a complex sugar called glycogen. Pompe patients lack a working version of an enzyme called GAA. Nexviazyme is an infused version of that enzyme, designed with an enhanced sugar tag (bis-M6P) that helps it get into muscle cells more efficiently than older ERTs, clearing glycogen buildup and slowing muscle damage.

Trial Status

FDA-approved since August 2021 for late-onset Pompe disease (LOPD) based on Phase 3 COMET and Phase 2 mini-COMET studies. On June 30, 2026, Sanofi announced positive Phase 3 Baby-COMET results (NCT04910776) in infantile-onset Pompe disease (IOPD), meeting all primary and secondary endpoints. Sanofi plans to file for FDA label expansion in H2 2026.

The Two-Sided Case

▲ Bull Case5
Nexviazyme sales grew 17-26% YoY in 2025, reaching ~€790M annually, and the Pompe franchise (including Myozyme) hit €320M in Q1 2026 alone, showing strong commercial traction.
The Baby-COMET Phase 3 trial (June 30, 2026) was a clean win: met all primary and secondary endpoints in infantile-onset Pompe, with no serious adverse events reported. This unlocks a label-expansion opportunity into a new, underserved patient population.
Sanofi's Pompe franchise is deeply entrenched with treating physicians (two marketed ERTs) and has a head start on BioMarin/Amicus in commercial infrastructure.
Pompe disease market is projected to grow from ~$2.1B (2025) to $5.2B by 2035 (9.2% CAGR), per Emergen Research, giving Nexviazyme a long growth runway.
Sanofi has 16 analyst Buy/Strong Buy ratings vs. just 1 Sell; mean price target of $55.50 implies ~26.5% upside from the current ~$43.15.
▼ Bear Case5
BioMarin completed its $4.8B acquisition of Amicus Therapeutics in April 2026, adding the Pombiliti+Opfolda combo, a direct competitor that a meta-analysis suggested may outperform Nexviazyme in ERT-experienced late-onset Pompe patients.
The Danish Medicines Council found Nexviazyme, Myozyme, and Pombiliti+Opfolda clinically equivalent, opening the door to competitive tendering and pricing pressure across European markets.
Nexviazyme partially cannibalizes Sanofi's own older ERT Myozyme/Lumizyme, the total Pompe franchise grew only 2.4% YoY in Q1 2026 (€320M), suggesting market share shifts rather than pure expansion.
At ~€790M in 2025 sales, Nexviazyme represents only ~1.8% of Sanofi's €43.6B total revenue, even a label-expansion win moves the needle very modestly for the stock.
Sanofi abandoned a $755M Maze Therapeutics Pompe deal after FTC lawsuit, highlighting regulatory scrutiny of Sanofi's Pompe market dominance.

Upcoming Catalysts

  • July 8, 2026: Full Baby-COMET Phase 3 data presentation at the 19th International Congress on Neuromuscular Diseases (Florence, Italy).
  • H2 2026: FDA submission for infantile-onset Pompe disease label expansion.
  • July 30, 2026: Sanofi Q2 2026 earnings, Nexviazyme quarterly sales and franchise update.
  • 2027 (estimated): PDUFA decision on infantile-onset Pompe label expansion.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 11

Hover a chip for the title
1 sanofi.com2 fda.gov3 sanofi.com4 bnains.org5 pharmaceutical-technology.com6 biomarin.com7 navlindaily.com8 pompediseasenews.com9 pharmaphorum.com10 techtimes.com11 dcatvci.org